Illumina, Inc. (ILMN) News
Follow Illumina, Inc. (ILMN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 64 public stories across 29 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Illumina Shares Fall 17.7% After Third-Quarter Results
Illumina shares fell 17.7% in afternoon trading after the company reported third-quarter 2026 results and highlighted impacts from its placement on China's Unreliable Entities List.
EQUITY | Oct 30, 2026, 05:16 PM UTC
M
Illumina Falls After Missing Third-Quarter Revenue Targets
Illumina shares fell after the company missed its third-quarter revenue targets.
EARNINGS | Oct 30, 2026, 02:44 PM UTC
M
Illumina shares fall 11% premarket after Q3 revenue miss
EQUITY | Oct 30, 2026, 08:19 AM UTC
M
Illumina Reports Quarterly Results for Period Ended September 30
Illumina reported results for the quarter ended September 30; the report provides no figures or comparison details.
EQUITY | Oct 29, 2026, 10:48 PM UTC
M
Illumina Says Clinical Sequencing Demand Drove Q3 2026 Earnings Beat
Illumina management attributed the company’s Q3 2026 earnings beat to clinical sequencing demand.
EQUITY | Oct 29, 2026, 09:22 PM UTC
M
Illumina Q3 Adjusted Earnings and Revenue Rise
Illumina reported increases in Q3 adjusted earnings and revenue.
EQUITY | Oct 29, 2026, 09:08 PM UTC
M
Illumina falls 13.2% after third-quarter revenue miss
Illumina shares fell 13.2% to $254 after the company missed third-quarter revenue expectations.
EARNINGS | Oct 29, 2026, 09:00 PM UTC
M
Illumina Expects FY2026 Adjusted EPS of $5.40-$5.45
Illumina expects fiscal 2026 adjusted EPS of $5.40-$5.45, versus a FactSet estimate of $5.35.
EARNINGS | Oct 29, 2026, 08:30 PM UTC
M
Illumina Q3 Revenue Rises, Misses Estimates; Outlook Lifted
EQUITY | Oct 29, 2026, 08:24 PM UTC
M
Illumina Q3 net income rises 47% to $220 million
EARNINGS | Oct 29, 2026, 08:23 PM UTC
M
Illumina Reports Higher Q3 2026 Net Profit and Revenue
Illumina reported higher net profit and revenue for Q3 2026.
EQUITY | Oct 29, 2026, 08:23 PM UTC
M
Illumina Reports Third-Quarter Revenue of $1.13B
EQUITY | Oct 29, 2026, 08:21 PM UTC
M
Illumina Reports Third-Quarter Net Income of $220 Million
EARNINGS | Oct 29, 2026, 08:05 PM UTC
L
Illumina reports third-quarter EPS of $1.43
EARNINGS | Oct 29, 2026, 08:05 PM UTC
M
Illumina reports third-quarter adjusted EPS of $1.62
EARNINGS | Oct 29, 2026, 08:05 PM UTC
L
China Condemns US Move to Add Medical Firms to Forced-Labour List
China condemned the US move to add Chinese medical equipment firms to the Uyghur forced-labour list.
REGULATION | Oct 29, 2026, 06:39 AM UTC
M
US Bans Imports From Three Chinese Genomics Firms Over Xinjiang
The US barred imports from three Chinese genomics companies, citing alleged links to forced labor in Xinjiang.
REGULATION | Oct 28, 2026, 09:40 PM UTC
M
미국, 신장 강제노동 연루 이유로 BGI·MGI 제품 수입 금지
REGULATION | Oct 28, 2026, 03:45 PM UTC
M
US Bans Imports From BGI Genomics and MGI Tech Over Forced-Labor Links
The United States has prohibited imports from BGI Genomics and MGI Tech, citing alleged links to forced labor in Xinjiang.
REGULATION | Oct 28, 2026, 03:45 PM UTC
M
Illumina Q3'26 Results Preview: Revenue Estimated
Illumina is scheduled to report Q3'26 results on October 29 after market close. Revenue and EPS estimates are provided.
EQUITY | Oct 22, 2026, 11:01 AM UTC
L
Illumina launches BioInsight software platform
The company describes BioInsight as its first unified software environment for genomic and multiomic research.
EQUITY | Oct 14, 2026, 01:15 PM UTC
M
Illumina to announce third-quarter 2026 results on Oct. 29
Illumina (ILMN) said it will announce its third-quarter 2026 financial results on Thursday, October 29, 2026.
EQUITY | Oct 08, 2026, 08:08 PM UTC
M
Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data
Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7%
EQUITY | Oct 06, 2026, 07:52 AM UTC
M
Illumina Shares Jump Amid Analyst Target Hikes
Illumina's stock surged 7.7% following price target increases from Wall Street analysts. The upgrades are attributed to expectations of improved clinical sales and new business catalysts.
EQUITY | Oct 05, 2026, 09:10 PM UTC
L
Illumina Is Maintained at Outperform by Leerink Partners
Ratings actions from Benzinga: GMT) Illumina Price Target Raised to $300.00/Share From $220.00 by Leerink PartnersRatings actions from Benzinga
NEWS | Sep 29, 2026, 04:35 PM UTC
L
Illumina Price Target Raised to $305.00/Share From $225.00 by Piper Sandler
Ratings actions from Benzinga: GMT) Illumina Is Maintained at Overweight by Piper SandlerRatings actions from Benzinga
NEWS | Sep 28, 2026, 04:11 PM UTC
L
Grail Is Maintained at Buy by Canaccord Genuity
Ratings actions from Benzinga: GMT) Grail Price Target Raised to $150.00/Share From $80.00 by Canaccord GenuityRatings actions from Benzinga
NEWS | Sep 28, 2026, 12:50 PM UTC
H
Oracle, Qualcomm, Meta, Everpure, BlackBerry, MGM, Nebius, and More Stocks That Explain Today's Market — Barrons.com
By George Glover, Mariapaula Gonzalez, and Connor SmithStocks were mixed Thursday as the bond market's woes worsened and following a report that signaled potential progress in discussions between the U.S. and Iran.Oracle
GEOPOLITICS | Sep 24, 2026, 08:39 PM UTC
L
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test
By Elias SchisgallShares of Grail rose after the healthcare company said a U.S. regulatory committee voted to approve its Galleri multi-cancer early detection test.The stock was up 5.6% at $114.59 as of midday Thursday.
REGULATION | Sep 24, 2026, 04:23 PM UTC
L
Biotech Stocks At 52-Week Highs - TKNO, MRNA, ATRC, ILMN
SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on September 23, 2026, driven by key catalysts such as positive quarterly reports or results from clinical trials.Alpha Teknova Inc. (TKNO)Alpha T
NEWS | Sep 24, 2026, 09:42 AM UTC
L
GRAL’s Galleri Cancer Test Clears FDA Panel Safety Vote, Splits On Effectiveness
A U.S. Food and Drug Administration (FDA) advisory panel on Wednesday backed GRAIL’s Galleri multi-cancer blood test for adults aged 50 and older, voting that it looks safe and that its benefits outweigh its risks, while
REGULATION | Sep 23, 2026, 11:53 PM UTC
L
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy
A panel of outside experts advising the US FDA backed the safety of Grail's NASDAQ:GRAL blood-based cancer detection test, Galleri, on Wednesday, though members were divided on the evidence supporting its effectiveness.W
REGULATION | Sep 23, 2026, 09:43 PM UTC
L
Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test
By Colin KellaherTrading in shares of Grail is halted on Wednesday ahead of a Food and Drug Administration advisory committee meeting to discuss the diagnostic company's proposed multi-cancer blood test.Grail is seeking
REGULATION | Sep 23, 2026, 11:52 AM UTC
M
Grail shares surge ahead of FDA advisory meeting on documents
Shares of Grail surged 34% after the FDA released documents ahead of a Wednesday advisory committee meeting on whether the company’s multi-cancer blood test will be approved.
EQUITY | Sep 21, 2026, 10:57 PM UTC
M
Grail shares surge after FDA staff see no major test concerns
US FDA staff reviewers said they did not raise major concerns about the accuracy and safety of Grail’s multi-cancer blood test. Grail’s shares surged 35% on Monday.
EQUITY | Sep 21, 2026, 04:41 PM UTC
M
Grail stock jumps 33% ahead of FDA multi-cancer blood test review
Grail shares rose 33% ahead of an FDA advisory panel meeting this week to evaluate premarket approval for its blood test designed to detect multiple cancer types early.
EQUITY | Sep 21, 2026, 03:28 PM UTC
H
Illumina Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Illumina (NASDAQ: ILMN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcr
LIVE | Sep 18, 2026, 08:37 AM UTC
H
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE: LUXE ) rose sharply after the company reported fourth-quarter results. LuxExperience reporte
LIVE | Sep 16, 2026, 01:57 PM UTC
H
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The U.S. 10-year Treasury yield broke above 5% on Tuesday, and crude oil stormed past $105 a barrel, a combination that left every major U.S. equity index in the red at midday. President Donald Trump said on Truth Social
LIVE | Sep 15, 2026, 05:27 PM UTC
L
Illumina upgraded to Buy by UBS; price target raised to $260
UBS upgraded Illumina to Buy from Neutral and raised its price target to $260.00 per share from $135.00, according to Benzinga and TradingView News.
EQUITY | Sep 09, 2026, 01:38 PM UTC
L
UBS initiates buy on ILMN with $105 price target
UBS initiated a buy rating for ILMN and set a $105.00/Share price target.
EQUITY | Sep 09, 2026, 01:30 PM UTC
M
Bloom Energy set to join S&P 500 before Sept. 21
Bloom Energy Corp. is set to join the S&P 500 before the open on September 21, part of the quarterly rebalance, lifting it 5.63% premarket. Illumina and Everpure also join; ILMN up 1.04%, P up 2.70%.
EQUITY | Sep 08, 2026, 12:16 PM UTC
M
S&P 500 to add Bloom Energy, Everpure and Illumina Monday
S&P Dow Jones Indices said Bloom Energy (BE), Everpure (P) and Illumina (ILMN) will enter the S&P 500 before trading begins Monday, September 21, replacing existing constituents.
EQUITY | Sep 07, 2026, 09:46 PM UTC
M
BE, P and ILMN to join S&P 500 index
Bloom Energy shares jumped after-hours after S&P said on Friday that Bloom Energy (BE), Everpure (P) and Illumina (ILMN) will join its S&P 500, while Cheniere Energy (LNG) slipped.
EQUITY | Sep 04, 2026, 11:43 PM UTC
M
Bloom Energy to join S&P 500 in quarterly reshuffle
Bloom Energy is set to replace Molson… as the S&P 500 adds three new members this month, alongside Everpure and Illumina, in a quarterly reshuffle.
EQUITY | Sep 04, 2026, 10:16 PM UTC
L
AGNC Investment to Join S&P MidCap 400
AGNC Investment is set to join the S&P MidCap 400.
EQUITY | Sep 04, 2026, 09:27 PM UTC
L
Molson Coors to move from S&P 500 to S&P SmallCap 600 Sept. 21
Molson Coors is set to move from the S&P 500 to the S&P SmallCap 600 on Sept. 21.
EQUITY | Sep 04, 2026, 09:23 PM UTC
M
Bloom Energy, Illumina, and Everpure to join the S&P 500
Bloom Energy, Illumina, and Everpure are set to join the S&P 500.
EQUITY | Sep 04, 2026, 09:20 PM UTC
L
Illumina maintained at Buy by Argus Research
Argus Research maintained a Buy rating on Illumina, according to ratings actions cited by Benzinga.
EQUITY | Sep 03, 2026, 01:38 PM UTC
L
Novacyt S.A. master collaboration agreement with Illumina
Novacyt S.A. entered a master collaboration agreement with Illumina.
EQUITY | Sep 01, 2026, 06:01 AM UTC
L
Largest premium to VWAP COTY (+3.75%) TEM (+3.69%) ILMN (+3.3%) WHR (+2.89%) NDSN (+2.71%) RGEN (+2.55%) TPL (+2.49%) DG (+2.37%) LITE (+2.3
Largest premium to VWAP COTY (+3.75%) TEM (+3.69%) ILMN (+3.3%) WHR (+2.89%) NDSN (+2.71%) RGEN (+2.55%) TPL (+2.49%) DG (+2.37%) LITE (+2.36%) DE (+2.32%) (Russell 1000 names)
EQUITY | Aug 20, 2026, 03:22 PM UTC
L
Illumina guides FY revenue $4,600-4,640M
Illumina guides FY revenue higher
EARNINGS | Jul 30, 2026, 08:27 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
L
Illumina Raises FY2026 Adj EPS Guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 Est; Raises FY2026 Sales Guidance from $4.520B-$4.620B to $
Illumina (NASDAQ: ILMN ) raises FY2026 Adj EPS guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 analyst estimate. Raises FY2026 sales outlook from $4.520 billion-$4.620 billion to $4.600 billion-$4.640 billion vs $4.566
EARNINGS | Jul 30, 2026, 08:13 PM UTC
L
ILMN Q2 adj EPS $1.31 vs. est. $1.23; Q2 revs $1.16B vs. est. $1.13B; raises FY26 adjusted EPS view to $5.30-$5.40 from $5.15-$5.30 (est. $5
ILMN Q2 adj EPS $1.31 vs. est. $1.23; Q2 revs $1.16B vs. est. $1.13B; raises FY26 adjusted EPS view to $5.30-$5.40 from $5.15-$5.30 (est. $5.23) and boosts FY26 rev view to $4.6B-$4.64B from $4.52B-$4.62B (est. $4.57B);
EARNINGS | Jul 30, 2026, 08:12 PM UTC
L
ILMN Illumina RESULTS: Q2, Q2 ebit margin 21.1%, Q2 REV $1.159B vs. EST $1.130B, Q2 ADJ gross margin 68.2%, Q2 gross margin 66.4%, Q2 ADJ eb
ILMN Illumina RESULTS: Q2, Q2 ebit margin 21.1%, Q2 REV $1.159B vs. EST $1.130B, Q2 ADJ gross margin 68.2%, Q2 gross margin 66.4%, Q2 ADJ ebit margin 22.5%, Q2 ADJ EPS $1.31 vs. EST $1.23, Illumina Earnings Notes:, - Ill
EARNINGS | Jul 30, 2026, 08:08 PM UTC
L
ILMN ILMN ILMN - Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
ILMN ILMN ILMN - Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
EARNINGS | Jul 30, 2026, 08:06 PM UTC
H
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.
Implied EPS movers for tonight: AAPL +/-3.5%, AMZN +/-5.8%, MPWR +/-15.1%, MSTR +/-5.4%, COIN +/-6.8%, SYK +/-7.2%, RDDT +/-9.8%, DXCM +/-7.5%, RIVN +/-7.9%, NXT +/-16.8%, MTZ +/-14.6%, AJG +/-7.2%, GH +/-14.1%, CTVA +/-
EARNINGS | Jul 30, 2026, 05:58 PM UTC
H
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
DHR -12% premarket after results, guidance; Peers A -3%, TMO -3%, RVTY, ILMN down about 2%
EARNINGS | Jul 21, 2026, 12:30 PM UTC
L
ILMN Element Biosciences Prevails in German Patent Case Against Illumina Element Biosciences Prevails in German Patent Case Against Illumina
ILMN Element Biosciences Prevails in German Patent Case Against Illumina Element Biosciences Prevails in German Patent Case Against Illumina Munich Regional Court finds Illumina infringes Element sequencing intellectual
EQUITY | Jul 14, 2026, 12:11 PM UTC